Status:
WITHDRAWN
Cognitive and Psychiatric Effects of Linaclotide on Patients With Constipation
Lead Sponsor:
McMaster University
Conditions:
Constipation
Irritable Bowel Syndrome
Eligibility:
All Genders
18-65 years
Brief Summary
Irritable Bowel syndrome - constipation predominant (IBS-C) is a chronic and disabling,disorder of the gut that is characterized by abdominal pain or discomfort. Approximately 50% of patients with IBS...
Detailed Description
Irritable bowel syndrome (IBS) is a chronic, disabling functional gastrointestinal disorder that is characterized by abdominal pain or discomfort and a disturbance in bowel habit. It has long been rec...
Eligibility Criteria
Inclusion
- IBS-C or CIC as defined by Rome III criteria
- able to provide and sign informed consent
- age 18-65 years
Exclusion
- Previous diagnosis of bipolar, schizophrenia, or schizoaffective disorder
- psychosis
- active suicidal thoughts
- presence of a major neurocognitive disorder, delirium or other cognitive disorder
- active substance dependence ( including the use of cannabis more than 3 times per week
- active eating disorder
- pregnant or breastfeeding
Key Trial Info
Start Date :
March 1 2016
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2021
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT03342287
Start Date
March 1 2016
End Date
March 1 2021
Last Update
August 31 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
McMaster University Medical Centre
Hamilton, Ontario, Canada, L8N3Z5